Device Cardiovascular

Fusion Ablation System

Payments companies reported to CMS as associated with Fusion Ablation System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$14Kassociated payments (2023-2025)
16clinicians with associated payments
1company reporting

By year

2023 $7,400
2024 $6,450

Payments reported as associated with Fusion Ablation System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Thoracic Surgery (Cardiothoracic Vascular Surgery) $8,174
Cardiovascular Disease $2,500
Physician Assistant $1,619
Acute Care (Nurse Practitioner) $541
Surgery $210
Family $150

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Fusion Ablation System

These are the largest totals companies reported as associated with Fusion Ablation System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Kevin Makati Lutz, FL Cardiovascular Disease $2,500.00
Andrew Sherman Tampa, FL Thoracic Surgery (Cardiothoracic Vascular Surgery) $2,500.00
Kathryn O'Keefe Cincinnati, OH Thoracic Surgery (Cardiothoracic Vascular Surgery) $2,250.00
Christopher Mings Fort Pierce, FL Physician Assistant $1,618.66
Guangqiang Gao Pomona, CA Thoracic Surgery (Cardiothoracic Vascular Surgery) $1,061.45
Shawn Shah Cleveland, OH $656.66
Anita Krueger Fort Worth, TX Thoracic Surgery (Cardiothoracic Vascular Surgery) $586.94
Sunita Boparai Los Angeles, CA Acute Care (Nurse Practitioner) $541.14
Edward Soltesz Cleveland, OH Thoracic Surgery (Cardiothoracic Vascular Surgery) $511.28
Jiantao Xiao Buffalo, NY Thoracic Surgery (Cardiothoracic Vascular Surgery) $370.00

Prescribed Fusion Ablation System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.